【摘要】 目的　评价盐酸吡格列酮治疗2型糖尿病的有效性及安全性。方法　用多中心随机双盲平行对照方法,将已合用磺脲类和双胍类药物的2型糖尿病患者随机分为2组:试验组口服吡格列酮,每日30mg;对照组服用安慰剂。各118例,疗程12周。结果　试验组空腹血糖、餐后2h血糖有明显下降(P<0. 01);糖化血红蛋白2组均有下降,试验组为-1. 06%,对照组为-0. 51%,均P<0. 01。2组胰岛素水平均无明显变化。治疗后,试验组高密度脂蛋白胆固醇升高了0. 11mmol·L-1 (P<0. 01),低密度脂蛋白胆固醇下降了0. 21mmol·L-1(P<0. 01),血压下降有统计学意义(P<0. 01),体重指数升高了0. 36 (P<0. 01)。试验组中,仅1例因中度肝功能异常退出试验,水肿较常见,程度轻。其他不良事件发生率2组相近。结论　口服降糖药后血糖控制不佳的2型糖尿病患者,加用盐酸吡格列酮30mg,可显著降低血糖,提高胰岛素敏感性,改善高血压状态,病人耐受性较好。更多还原

【Abstract】 Objective To evaluate the efficacy and safety of pioglitazone in the treatment of type 2 diabetes. Methods Two hundreds and thirty six patients with type 2 diabetes who have received metformin and sulfonylureas treatment were included in this 12-week, multicenter, double-blind study. They were divided randomly into trial group (pioglitazone 30 mg one time a day) and contro group (placebo). Results Fasting and post prandial plasma glucose levels of the trial group decreased significantly (P< 0.01 ). The mean levels of glycosylated hemoglobin levels decreased by 1.06 % (P<0.01) in the trial group and by 0.51% (P<0.01) in the control group. Meanwile, fasting and postprandial plasma insulin levels of the two groups unchanged significantly. High-density lipoprotein cholesterol increased by 0.11 mmol·L -1 (P<0.01) and low-density lipoprotein cholesterol decreased by 0.21 mmol·L -1 (P<0.01) in the trial group at week 12 vs baseline. Blood pressure of the trial group decreased significantly (P<0.01). Body mass index increased (0.36, P<0.01) in the trial group. One case in the trial group dropped off because of moderate liver damage, mild edema occurred frequently.The proportion of patients reporting other adverse experiences was comparable between two groups. Conclusion Treatment with pioglitazone 30 mg qd in patients plus previous metformin-sulfonylureas can improve glycemic control, improve insulin sensitivity and have possibility to improve lipid metabolism and hypertention. Pioglitazone 30 mg qd is generally all tolerated.更多还原